DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882
Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261
Novick D, Montgomery W, Aguado J, Peng XM, Haro JM. Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients. Neuropsychiatr Dis Treat. 2016 Apr 11;12:795-800. doi: 10.2147/NDT.S90134
Coles T, Coon C, DeMuro C, McLeod LD, Gnanasakthy A. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2014 May 19;10:887-95. doi: 10.2147/NDT.S55220. eCollection 2014
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.